DAN-222
- Generic Name
- DAN-222
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- HER2-negative Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Dantari, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05261269
- Locations
- 🇺🇸
UCLA - Parkside Cancer Center, Santa Monica, California, United States
🇺🇸Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath